EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors

September 1, 2010

OXFORD, England and LANGHORNE, Pennsylvania, September 1, 2010
/PRNewswire/ — EUSA Pharma, a transatlantic specialty pharmaceutical company
focused on oncology, pain control and critical care, today announced the
appointment of Stephen A. Stamp to the company’s Board as an independent
Non-Executive Director.

Mr Stamp has extensive experience of the specialty pharmaceutical sector
having previously held Board-level roles at Xanodyne Pharmaceuticals Inc. and
Shire Pharmaceuticals Plc, and most recently as Chief Financial Officer of
K-V Pharmaceutical Company. Mr Stamp has considerable financial expertise
developed during a career spanning over 25 years, including more than 10
years in corporate finance and investment banking. He is an Associate Member
of the Institute of Chartered Accountants.

“I want to warmly welcome Stephen to EUSA Pharma,” said Rolf Stahel, EUSA
Pharma’s Chairman. “Since its foundation four years ago, EUSA has established
itself as a successful transatlantic specialty pharma business, and is now
entering its next phase of rapid and profitable growth. Stephen’s financial
expertise, and history of success in our industry, will prove an important
asset as we transition EUSA into one of the most successful companies in its

Commenting on his appointment, Stephen A. Stamp said, “Having witnessed
EUSA’s impressive growth, I am excited to be helping the company achieve its
ambitious plans. Having already built a robust commercial infrastructure in
the US and Europe, and a wider global distribution network, I believe EUSA is
well placed for future success, and I welcome the opportunity to be part of
the company’s continued rapid development.”

About EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical
company focused on in-licensing, developing and marketing late-stage
oncology, pain control and critical care products. The company currently has
eight marketed products, including Caphosol(R) for the treatment of oral
mucositis, a common and debilitating side-effect of radiation therapy and
high dose chemotherapy, Erwinase(R) and Kidrolase(R) for the treatment of
acute lymphoblastic leukemia, Collatamp(R) G, a surgical implant impregnated
with the antibiotic gentamicin, ProstaScint(R) for imaging the extent and
spread of prostate cancer and Quadramet(R) for the treatment of pain in
patients whose cancer has spread to the bones. EUSA also has several products
in late-stage development.

Founded in 2006, EUSA Pharma is supported by a consortium of leading life
science capital investors, comprising Essex Woodlands, 3i, Goldman Sachs,
Advent Venture Partners, SV Life Sciences, TVM Capital, NeoMed and NovaQuest.
Since its foundation, the company has raised over $300 million, and completed
several significant transactions, including the acquisitions of Cytogen
Corporation, Talisker Pharma Limited, the French biopharmaceutical company
OPi SA and the European antibiotic and pain control business of Innocoll
Pharmaceuticals Inc. Key to its rapid growth strategy is the company’s
established commercial infrastructure in the US, pan-European presence
covering over 20 countries and wider distribution network in a further 80
territories. EUSA Pharma plans to continue its aggressive program of
acquisitions and in-licensing, in line with its ambitious target to become
the leading specialty company in its areas of therapeutic and geographic


    Bryan Morton
    Chief Executive EUSA Pharma
    Tel: +44(0)1865-784255

    Rob Budge
    RJB Communications
    Tel: +44(0)1865-760969
    Mobile: +44(0)7710-741241


Source: newswire

comments powered by Disqus